文献速递鼻科头颈外科

头颈癌放疗后慢性鼻窦炎:台湾人群队列研究

Chronic rhinosinusitis after radiotherapy in patients with head and neck cancer: a population-based cohort study in Taiwan.
PubMed 文献 · Int Forum Allergy Rhinol · 2020-02-13

该回顾性队列研究利用台湾2005年纵向健康保险数据库,纳入2005至2008年新诊断头颈癌患者701例,按治疗方式分为单纯放疗组、含放疗组和无放疗组,比较治疗后5年内慢性鼻窦炎(CRS)发生率。结果显示单纯放疗组和含放疗组CRS风险均显著高于无放疗组,提示放疗是头颈癌患者发生CRS的主要危险因素。

要点

  • 头颈癌放疗后5年内CRS总体发生率为7%。
  • 单纯放疗组5年CRS发生率为12%,含放疗组为9.3%,无放疗组为4.5%。
  • 单纯放疗组和无放疗组CRS风险比分别为6.76和2.91。

核心结论

  • 放疗是头颈癌患者治疗后发生慢性鼻窦炎的主要危险因素。

研究设计与样本

  • 回顾性队列研究,利用台湾2005年纵向健康保险数据库,纳入2005年1月1日至2008年12月31日新诊断头颈癌患者701例。
  • 按治疗方式分为单纯放疗组、放疗联合其他治疗组(含放疗组)和无放疗组,观察治疗后CRS发生情况。

主要发现

  • 701例患者中7%在初始治疗后5年内发生CRS。
  • 单纯放疗组、含放疗组和无放疗组的5年CRS发生率分别为12%、9.3%和4.5%。
  • 与无放疗组相比,单纯放疗组发生CRS的风险比为6.76(95%CI 2.60-17.5),含放疗组为2.91(95%CI 1.60-5.31)。

临床怎么用

  • 头颈癌患者接受放疗后应警惕慢性鼻窦炎的发生风险,必要时进行耳鼻咽喉科评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis (CRS) is a common post-radiotherapy (RT) side effect in patients with nasopharyngeal cancer (NPC). However, whether RT is a risk factor for CRS in patients with other types of head and neck cancer remains unclear. This study investigated the association, if any, between CRS and RT in patients with head and neck cancer. METHODS: This retrospective cohort study included the data of patients newly diagnosed as having head and neck cancer between January 1, 2005, and December 31, 2008, from the 2005 Longitudinal Health Insurance Database. Patients were categorized into the following groups according to the treatment regimens received: RT alone (RT-alone), RT combined with other treatments (any-RT), and treatments without RT (no-RT). The outcome was the occurrence of CRS after treatment. RESULTS: Of the 701 patients, 7% experienced CRS within 5 years after initial treatment. Patients were divided into subgroups according to different treatment policies, and the RT-alone group, any-RT group, and no-RT group had 5-year incidence of CRS of 12%, 9.3%, and 4.5%, respectively. Patients in the RT-alone and any-RT groups exhibited an increased risk of CRS compared with patients in the no-RT group (hazard ratio: 6.76 and 2.91; 95% confidence interval: 2.60 to 17.5 and 1.60 to 5.31, respectively). CONCLUSION: This is the first nationwide population-based cohort study to evaluate the risk of posttreatment CRS in patients with head and neck cancer. Our findings indicate that RT is a major risk factor for CRS. Thus, physicians should consider this potential risk in patients with head and neck cancer after RT.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Lu YT, Lu YC, Cheng HC, et al. Chronic rhinosinusitis after radiotherapy in patients with head and neck cancer: a population-based cohort study in Taiwan. Int Forum Allergy Rhinol. 2020. PMID: 32052933. doi:10.1002/alr.22526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。